Live from asco 2025 | ascentage pharma presents clinical data on bcl-2 inhibitor lisaftoclax in venetoclax-refractory patients in oral report

Rockville, md. and suzhou, china, june 02, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a phase ib/ii study of the investigational bcl-2 inhibitor, lisaftoclax (apg-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naÏve (tn) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st american society of clinical oncology (asco) annual meeting.
AAPG Ratings Summary
AAPG Quant Ranking